HARVONI® approved in Brazil

Grupo Biotoscana expects to introduce the product into the market in Q2 2018.

Montevideo, Uruguay, December 5, 2017. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces HARVONI® (90 mg ledipasvir / 400 mg sofosbuvir) approval by ANVISA, in Brazil. The last step of the registration process is price approval by CMED.

GBT will be responsible for market access, commercialization, distribution in Brazil. Gilead Sciences will continue to be responsible for supplying these treatment options directly to the Brazilian Ministry of Health.

GBT is very enthusiastic to be able to expand this existing partnership and broaden the HCV treatment options by adding leading brand HARVONI® to better serve more patients and doctors with this serious infectious disease, explains Mariano García-Valiño, CEO of GBT.

See the full article.

About GBT-Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.

About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

About HARVONI
HARVONI® (90 mg ledipasvir / 400 mg sofosbuvir) is a prescription medicine used with or without ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1, 4, 5 or 6 infections. It is not known if HARVONI is safe and effective in children under 18 years of age. HARVONI® are registered trademarks of Gilead Sciences, Inc. or its related companies..

Forward-Looking Statements (GBT)
This release includes forward-looking statements concerning a transaction between Gilead Sciences and GBT-Grupo Biotoscana, including expectations regarding the applicability of predictions to the commercialization of certain products. GBT-Grupo Biotoscana disclaims any obligation to update any forward-looking statement, except as required by applicable law.